Ascher D P, Becker J A, Yoder B A, Weisse M, Waecker N J, Heroman W M, Davis C, Fajardo J E, Fischer G W
Department of Pediatrics, Wilford Hall Air Force Medical Center, San Antonio, Tex.
J Perinatol. 1993 May-Jun;13(3):212-6.
Early-onset group B streptococci (GBS-EOS) sepsis may be prevented by intrapartum antibiotics administered for GBS maternal colonization, premature labor, or prolonged rupture of membranes. We sought to identify cases of neonatal GBS sepsis after apparent failure of intrapartum chemotherapy and to determine the factors associated with failure of intrapartum antibiotics in these cases. We identified 96 GBS blood culture-positive infants at five military medical centers from 1987 to 1990. Eighteen (18.7%) of these infants had mothers who had received intrapartum antibiotics; 16 of 18 cases were early-onset disease, 15 of which initially had symptoms at less than 1 hour of age. Two infants had late-onset disease develop at 3 weeks of age. At least one perinatal risk factor (prematurity, prolonged rupture of membranes > 12 hours, maternal fever) was present in each of the 16 cases. Indications for intrapartum antibiotics were suspected chorioamnionitis (13 cases), GBS colonization and prolonged rupture of membranes or prematurity (3), and GBS colonization alone (2). Maternal antibiotics included ampicillin (14 cases), cephadyl (1), vancomycin (1), clindamycin (1), and gentamicin alone (1). The median number of doses of ampicillin before delivery was 1 (range, 1 to 21), which was administered at a median of 4 hours (range, 1 to 84) before birth. The mean dose of ampicillin was 1.8 gm/dose (range, 1 to 2 gm/dose). Two of 16 (12.5%) infants with GBS-EOS died as a result of GBS sepsis. In our population of neonates with GBS-EOS, 18.4% (16 of 87) of the infants had positive blood cultures despite intrapartum antibiotics. Intrapartum antibiotics may fail to prevent GBS sepsis in a number of infants born to mothers colonized with GBS or to those with acute chorioamnionitis.
早发型B族链球菌(GBS-EOS)败血症可通过对GBS产妇定植、早产或胎膜早破进行产时抗生素治疗来预防。我们试图识别在产时化疗明显失败后发生的新生儿GBS败血症病例,并确定这些病例中产时抗生素治疗失败的相关因素。我们在1987年至1990年期间于五个军事医疗中心识别出96例GBS血培养阳性的婴儿。其中18例(18.7%)婴儿的母亲在产时接受了抗生素治疗;18例中的16例为早发型疾病,其中15例在出生后1小时内出现初始症状。2例婴儿在3周龄时发生晚发型疾病。16例中的每一例均存在至少一种围产期危险因素(早产、胎膜早破>12小时、母亲发热)。产时抗生素治疗的指征包括疑似绒毛膜羊膜炎(13例)、GBS定植及胎膜早破或早产(3例),以及单纯GBS定植(2例)。产妇使用的抗生素包括氨苄西林(14例)、头孢噻啶(1例)、万古霉素(1例)、克林霉素(1例)和单独使用庆大霉素(1例)。分娩前氨苄西林的中位剂量为1剂(范围为1至21剂),给药时间中位数为出生前4小时(范围为1至84小时)。氨苄西林的平均剂量为1.8克/剂(范围为1至2克/剂)。16例GBS-EOS婴儿中有2例(12.5%)因GBS败血症死亡。在我们的GBS-EOS新生儿群体中,18.4%(87例中的16例)婴儿尽管在产时接受了抗生素治疗,但血培养仍呈阳性。产时抗生素治疗可能无法预防GBS定植母亲或患有急性绒毛膜羊膜炎母亲所生的许多婴儿发生GBS败血症。